Status:
COMPLETED
The Role of High Dose Co-trimoxazole in Severe Covid-19 Patients
Lead Sponsor:
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Conditions:
COVID-19 Pneumonia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Coronavirus Disease 19 (COVID-19) is a worldwide pandemic and a major global health concern which is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The newly emerged Coronavir...
Detailed Description
The newly emerged Coronavirus disease 2019 (COVID-19), which was first identified in Wuhan, China, has swept through 219 countries, killing a staggering number of people. The World Health Organization...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Confirmed COVID-19 patients by RT-PCR
- Clinically suspected COVID-19 patients
- Age \> 18 years
- Patients requiring oxygen at least\> 5L/min up to 15 L/min (by FM/ NRM)to maintain saturation \>92% to 96%
- NOTE: Clinically suspected COVID-19 = fever (Temperature \>37.8 Degree Celsius) + respiratory symptoms + Radiological evidences Exclusion criteria
- Multi-organ failure
- Severe ARDS (requiring HFNC orventilatory support on presentation in the form ofinvasive or non-invasive ventilation)
- Septic Shock
- Severe liver disease
- Acute Heart Failure
- Acute Kidney Injury (where GFR\< 15 and plasma-sulfamethoxazoleconcentration cannot be monitored)
- Drug allergy/intolerance to co-trimoxazole / Sulphar sensitivity
- Pregnancy
Exclusion
Key Trial Info
Start Date :
May 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 14 2021
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT04884490
Start Date
May 15 2021
End Date
November 14 2021
Last Update
March 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bangabandhu Sheikh Mujib Medical University
Dhaka, Bangladesh, 1200